Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
| ▸ | HRAS | P01112 | 1/20 | 0.37 |
| ▸ | MAG | P20916 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10541712 | 1.00 | L3MBTL1 (0.77) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL7570170 | 1.00 | L3MBTL1 (0.77) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL15514841 | 1.00 | L3MBTL1 (0.77) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL6810084 | 1.00 | L3MBTL1 (0.77) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL2341511 | 1.00 | L3MBTL1 (0.77) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL10542231 | 1.00 | L3MBTL1 (0.77) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL15515027 | 0.93 | L3MBTL1 (0.66) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL20591189 | 0.93 | L3MBTL1 (0.66) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL7572891 | 0.93 | KMT2A (0.69) | L3MBTL1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL10544363 | 0.91 | L3MBTL1 (0.64) | L3MBTL1KMT2AMEN1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | THERAPEUTIKOS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | THERAPEUTIKOS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2022051575-A2 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | HASSAN AMEER E (US) | 2022-03-10 | — | — | WO | disclosed |
| US-5654412-A | CONVERGENT SYNTHESIS VIA TWO DISACCHARIDE SUBCOMPONENTS; SIMPLIFICATION, HIGH YIELD | GLYCOMED INCORPORATED (US) | 1997-08-05 | — | — | US | disclosed |
| US-4370265-A | N-ACETYLMURAMYL-L-ALANYL-D-GLUTAMIC ACID | AGENCE NATIONALE DE VALORISATION (FR) | 1983-01-25 | — | — | US | disclosed |
| US-4327085-A | A MUR-NACETYL-ALANINE-GLYTAMIC ACIOD FOR STIMULATING IMMUNE RESPONSE | AGENCE NATIONAL DE VALORISATION DE LA RECHERACHE (ANVAR) (FR) | 1982-04-27 | — | — | US | disclosed |
| US-4323559-A | BACTERICIDES | AGENCIE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1982-04-06 | — | — | US | disclosed |
| US-4235771-A | ACYL-MURAMIC ACID WITH PEPTIDE CHAIN LINKED THERETO | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1980-11-25 | — | — | US | disclosed |
| US-4186194-A | Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | ACE, ACE2, MAVS | L3MBTL1 1722/4885KMT2A 3942/4885MEN1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.